Jul 24, 2025 08:15AM Aditxt subsidiary invited to submit DOD proposal for ovarian cancer test

Jul 7, 2025 08:16AM Aditxt (ADTX) launches Bitcoin treasury strategy to fund biotech ventures

Jun 20, 2025 05:04PM Aditxt, Inc (ADTX) Files for 50M Share Offering by Selling Stockholders

Jun 9, 2025 08:15AM Aditxt, Inc (ADTX) appoints Saundra Pelletier to Board

Apr 14, 2025 08:15AM Aditxt's (ADTX) Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions

Apr 11, 2025 08:15AM Aditxt, Inc (ADTX) Issues Weekly Update to Highlight Recent Events

Apr 9, 2025 08:15AM Aditxt, Inc (ADTX) Regains Compliance with Nasdaq Listing Requirements

Mar 18, 2025 07:37AM Appili Therapeutics Provides Update on Going-Private Transaction with Aditxt (ADTX)

Mar 17, 2025 08:15AM Aditxt, Inc (ADTX) Provides Business Status Overview

Mar 12, 2025 04:15PM Aditxt, Inc (ADTX) Announces 1:250 Reverse Share Split

Mar 6, 2025 08:15AM Aditxt, Inc (ADTX) Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100

Feb 21, 2025 08:15AM Aditxt, Inc (ADTX) Subsidiary Pearsanta Engages Dominari Securities for its IPO

Jan 13, 2025 08:15AM Aditxt's (ADTX) Board Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Nov 8, 2024 08:35AM Aditxt, Inc (ADTX) Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Oct 31, 2024 08:32AM Aditxt's (ADTX) Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801

Oct 29, 2024 08:16AM Aditxt, Inc (ADTX) Appoints Sylvia Hermina to its Board

Oct 10, 2024 08:15AM Aditxt's (ADTX) Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval

Oct 3, 2024 08:16AM Aditxt, Inc (ADTX) Issues Shareholder Update and 2024 Year-End Plan

Sep 27, 2024 08:15AM Aditxt, Inc (ADTX) Announces 1:40 Reverse Share Split

Sep 24, 2024 08:15AM Evofem Biosciences (EVFM) Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt (ADTX)

Sep 6, 2024 05:09PM Aditxt, Inc (ADTX) Files for $150M Share Offering

Sep 4, 2024 08:15AM Aditxt (ADTX) Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients

Aug 26, 2024 08:16AM Aditxt's (ADTX) Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President

Aug 21, 2024 08:16AM Aditxt, Inc (ADTX) Announces Third Amendment to Arrangement Agreement with Appili Therapeutics

Aug 20, 2024 08:17AM Evofem Biosciences (EVFM) Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution

Aug 13, 2024 08:15AM Aditxt, Inc (ADTX) Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting

Aug 9, 2024 08:00AM Aditxt, Inc (ADTX) Announces 1.13M Share Offering at $1.06/sh

Aug 7, 2024 08:15AM Aditxt's (ADTX) Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer

Jul 17, 2024 06:31AM Aditxt, Inc (ADTX) and Evofem (EVFM) Amend and Restate Merger Agreement, now Target September 30 Closing

Jul 11, 2024 04:33PM Aditxt, Inc (ADTX) Files Mixed Shelf

Jun 11, 2024 08:36AM Evofem Biosciences (EVFM) Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter